AEON Biopharma, Inc.
AEON
$0.40
-$0.0093-2.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.64M | 15.70M | 18.97M | 20.60M | 19.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.82M | 33.70M | 43.96M | 50.17M | 52.84M |
| Operating Income | -27.82M | -33.70M | -43.96M | -50.17M | -52.84M |
| Income Before Tax | 42.01M | 13.68M | -305.52M | -485.01M | -384.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.01 | 13.68 | -305.52 | -485.01 | -384.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.01M | 13.68M | -305.52M | -485.01M | -384.63M |
| EBIT | -27.82M | -33.70M | -43.96M | -50.17M | -52.84M |
| EBITDA | -27.73M | -33.60M | -43.86M | -50.07M | -52.74M |
| EPS Basic | 68.70 | 14.10 | -362.70 | -674.88 | -456.02 |
| Normalized Basic EPS | -74.38 | -72.73 | -97.70 | -103.47 | -42.28 |
| EPS Diluted | 68.14 | 13.82 | -362.70 | -674.88 | -456.02 |
| Normalized Diluted EPS | -74.37 | -72.73 | -97.70 | -103.47 | -42.28 |
| Average Basic Shares Outstanding | 2.16M | 2.12M | 2.41M | 3.80M | 5.21M |
| Average Diluted Shares Outstanding | 2.16M | 2.12M | 2.41M | 3.80M | 5.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
